Neurocrine Biosciences, Inc.

Neurocrine Biosciences Misses on Revenue, Stock Down 4.64%

Neurocrine Biosciences reported a wider-than-expected loss per share, which contributed to a negative stock reaction, dropping 4.64%. The lack of revenue information and no guidance update may raise concerns among investors about the company's future performance. Management's cautious tone suggests they are aware of the challenges ahead, which could impact investor confidence.